Allergic Bronchopulmonary Aspergillosis (ABPA) Market is expected to surpass USD 1.1 billion by 2034

Allergic bronchopulmonary aspergillosis (ABPA) is a rare, hypersensitivity reaction caused by the fungus Aspergillus fumigatus, primarily affecting patients with asthma or cystic fibrosis (CF). It is characterized by chronic airway inflammation, recurrent pulmonary infiltrates, and bronchiectasis, leading to progressive lung damage if untreated.

Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71757

As asthma and CF cases rise globally, awareness and diagnosis of ABPA are improving. Current management involves oral corticosteroids and antifungal agents, but long-term steroid use raises safety concerns. The market is expanding due to new biologics, antifungal innovation, and precision diagnostic tools.

Market Overview
• Market Size (2024): USD 580 million
• Forecast (2034): USD 1.1 billion
• CAGR (2025-2034): 6.7%

Growth is driven by rising asthma prevalence, increasing bronchiectasis detection, and new treatment modalities targeting immunological pathways.

Key Highlights:
• ABPA prevalence is estimated at 2-3% in asthma patients and up to 15% in CF patients.
• Corticosteroids remain first-line, with itraconazole and voriconazole as adjunct antifungals.
• Monoclonal antibodies (omalizumab, mepolizumab) showing strong promise.
• Diagnostics shifting from imaging alone to IgE serology and molecular assays.

Segmentation Analysis
By Product Type:
• Corticosteroids
o Prednisone
o Methylprednisolone

• Antifungal Therapies
o Azoles (Itraconazole, Voriconazole, Posaconazole)

• Biologics
o Omalizumab (anti-IgE)
o Mepolizumab (anti-IL-5)
o Dupilumab (anti-IL-4/IL-13 - pipeline use)

• Diagnostics
o Serum IgE Testing
o Skin Prick Tests
o Molecular Diagnostics (PCR, fungal antigen detection)

By Platform:
• Small Molecules (steroids, antifungals)
• Biologics (monoclonal antibodies)
• Diagnostics

By Technology:
• Immunodiagnostics (IgE, IgG)
• Imaging (CT for bronchiectasis)
• Molecular PCR/Antigen-Based Detection

By End Use:
• Hospitals & Pulmonology Clinics
• Diagnostic Laboratories
• Specialty CF Centers
• Research Institutes

By Application:
• Asthma-Associated ABPA
• CF-Associated ABPA
• Bronchiectasis-Dominant ABPA
• Clinical Research
Segmentation Summary:
Corticosteroids remain standard, but biologics and antifungals are reshaping the treatment landscape. Diagnostics are advancing toward molecular testing and immunoassays for accurate detection.

Explore Full Report here: https://exactitudeconsultancy.com/reports/71757/allergic-bronchopulmonary-aspergillosis-market

Regional Analysis
North America
• ~40% share in 2024.
• High asthma and CF prevalence driving strong ABPA diagnosis and treatment rates.
• Early adoption of biologics (omalizumab, mepolizumab).
Europe
• ~30% share.
• Germany, UK, and France leading in CF patient care and biologics use.
• EMA approvals of novel antifungals supporting adoption.
Asia-Pacific
• Fastest-growing region with CAGR of ~7.8%.
• Rising asthma burden in India, China, and Southeast Asia.
• Limited awareness but increasing adoption of antifungals and diagnostics.
Middle East & Africa
• Smaller market but rising respiratory infection and asthma prevalence.
• Limited biologic availability outside tertiary centers.
Latin America
• Brazil and Mexico driving demand.
• Expanding diagnostic adoption and increasing biologic penetration.
Regional Summary:
North America and Europe dominate due to biologics and strong diagnostic infrastructure, while Asia-Pacific grows fastest due to rising asthma prevalence and healthcare investments.

Market Dynamics
Key Growth Drivers:
• Rising asthma and CF patient pool.
• Increased detection of bronchiectasis via CT imaging.
• Expansion of biologics in severe allergic airway diseases.
• Improved diagnostic immunoassays for ABPA.

Key Challenges:
• Long-term corticosteroid complications.
• Antifungal resistance in azole therapy.
• High biologic costs limiting access.
• Underdiagnosis in low- and middle-income countries.

Latest Trends:
• Monoclonal antibodies repurposed for ABPA (omalizumab, dupilumab).
• Combination regimens of antifungals and biologics.
• AI-driven imaging for bronchiectasis diagnosis.
• Integration of ABPA management into CF and severe asthma care pathways.

Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71757

Competitor Analysis
Major Players in the Market:
• Roche Holding AG (Xolair - Omalizumab)
• GlaxoSmithKline plc (Nucala - Mepolizumab)
• Sanofi S.A. & Regeneron (Dupixent - Dupilumab)
• Novartis AG
• Pfizer Inc. (Itraconazole, Voriconazole)
• Merck & Co., Inc. (Posaconazole)
• Teva Pharmaceutical Industries Ltd.
• Dr. Reddy's Laboratories Ltd.
• Cipla Ltd.
• Thermo Fisher Scientific Inc. (diagnostics)

Competitive Summary:
Roche, GSK, and Sanofi dominate with biologics, while Pfizer and Merck lead antifungal therapies. Thermo Fisher drives immunodiagnostics. Competition focuses on biologic expansion, antifungal innovation, and diagnostic integration.

Conclusion
The Allergic Bronchopulmonary Aspergillosis (ABPA) Market, valued at USD 580 million in 2024, is projected to reach USD 1.1 billion by 2034, growing at a CAGR of 6.7%. Rising asthma prevalence, biologic adoption, and diagnostic improvements will continue to expand the market.

Key Takeaways:
• Corticosteroids remain first-line, but biologics are the fastest-growing segment.
• North America and Europe dominate, while Asia-Pacific grows fastest.
• Diagnostics are shifting toward molecular and immunoassay-based approaches.
• Combination therapies will play a central role in reducing relapse and resistance.

The next decade will transform ABPA management, moving from steroid-heavy regimens to biologics, precision diagnostics, and integrated respiratory care models, creating strong opportunities for pharma innovators, diagnostics firms, and specialty clinics.

This report is also available in the following languages : Japanese (アレルギー性気管支肺アスペルギルス症市場), Korean (알레르기성 기관지폐 아스페르길루스증 시장), Chinese (过敏性支气管肺曲霉病市场), French (Marché de l'aspergillose bronchopulmonaire allergique), German (Markt für allergische bronchopulmonale Aspergillose), and Italian (Mercato dell'aspergillosi broncopolmonare allergica), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/71757/allergic-bronchopulmonary-aspergillosis-market#request-a-sample

Our More Reports:

Genotoxicity Testing Market
https://exactitudeconsultancy.com/reports/72432/genotoxicity-testing-market

RNA Therapeutics Fundamental Analysis Market
https://exactitudeconsultancy.com/reports/72431/rna-therapeutics-fundamental-analysis-market

EZH2 Inhibitors Market
https://exactitudeconsultancy.com/reports/72430/ezh2-inhibitors-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.